President, Drug Development and Commercial Operations, Europe

Thermo Fisher Scientific

Prior to his current role, Drew was a member of Thermo Fisher’s Life Sciences Solutions leadership team. Over a three-year period, he led Thermo Fisher’s Licensing and Commercial Supply business, partnering with leading diagnostic, therapeutic and life sciences companies to incorporate Thermo Fisher’s products and intellectual property into commercial production. This included beads, reagents, chips, plastics and equipment used in PCR, microarray, CE and NGS-based diagnostic testing, antibody-labeled beads for use in CAR-T and other cell therapy processes, as well as cell lines, gene editing tools, enzymes and amidites for use in gene therapies and other life science applications.

Drew also led strategy and business development for Thermo Fisher’s $8 billion Life Sciences Solutions Group, overseeing strategic planning for the group, acquisitions including Affymetrix, Advance Scientifics, Finesse Solutions, MTI GlobalStem, LuBio, and Thermo Fisher’s investments in venture stage companies.
Prior to joining Thermo Fisher, Drew spent over two decades advising on healthcare industry mergers and acquisitions. He led Global Healthcare M&A for Barclays over a ten year period, during which it grew to become one of the top five advisory practices in global healthcare M&A, and personally advised clients in the pharmaceutical, biotechnology, and tools & diagnostics industries.

He began his career and spent 12 years at Merrill Lynch focused on healthcare M&A. Drew and his wife Cathy have two children, and enjoy sports, outdoor activities and travel. Drew received his BA in Economics & Political Science from Yale, cum laude, and his MBA from Stanford’s Graduate School of Business, where he was recognized as an Arjay Miller Scholar.